DelveInsight has launched a new report on “Ulcerative Colitis – Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “Ulcerative Colitis – Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
- The total prevalent population of Ulcerative Colitis in the 7MM in 2020 was 2,201,831. These cases are expected to rise by 2032, during the forecast period [2022–2032].
- According to DelveInsight’s analysis, in the 7MM, the United States reported the highest prevalent cases of Ulcerative Colitis, i.e., 1,008,823 which accounted for nearly 46% of the total 7MM cases, in the year 2020.
- Among the EU-5 countries, the highest number of cases of Ulcerative Colitis was in Germany, i.e., 342,785 cases in the year 2020.
Key benefits of the report:
- Ulcerative Colitis market report covers a descriptive overview and comprehensive insight of the Ulcerative Colitis epidemiology and Ulcerative Colitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Ulcerative Colitis market report provides insights on the current and emerging therapies.
- Ulcerative Colitis market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Ulcerative Colitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Ulcerative Colitis market.
Got queries? Click here to know more about Ulcerative Colitis Market Landscape.
Ulcerative Colitis Overview
Ulcerative colitis is usually only in the innermost lining of the large intestine (colon) and rectum. Forms range from mild to severe. Having ulcerative colitis puts a patient at increased risk of developing colon cancer.
The key players involved in the Ulcerative Colitis market:
- AbbVie and Boehringer Ingelheim
- Eli Lilly and Company
- Janssen
- Galapagos/Gilead
- Theravance Biopharma and Janssen
- Arena
- Landos Biopharma
- And others
The launch of the emerging therapies is expected to significantly impact the Ulcerative Colitis treatment scenario in the upcoming years:-
Drug covered
- Risankizumab (ABBV-066)
- Mirikizumab (LY3074828)
- Tremfya (Guselkumab)
- Filgotinib
- Izencitinib (TD-1473)
- Etrasimod (APD334)
- BT-11
- And others.
Table of Contents
1. Report Introd Ulcerative Colitis
2. Executive Summary
3. SWOT analysis
4. Ulcerative Colitis Patient Share (%) Overview at a Glance
5. Ulcerative Colitis Market Overview at a Glance
6. Ulcerative Colitis Disease Background and Overview
7. Ulcerative Colitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Ulcerative Colitis
9. Ulcerative Colitis Current Treatment and Medical Practices
10. Unmet Needs
11. Ulcerative Colitis Emerging Therapies
12. Ulcerative Colitis Market Outlook
13. Country-Wise Ulcerative Colitis Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Ulcerative Colitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Request for a sample report @ Ulcerative Colitis Market Outlook 2032.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/